Abstract 1223P
Background
Current data is suggesting better survival in various cancer types but increased anticancer treatment toxicity in female compared to male patients (pts). Here, we report a pooled analysis of sex-related differences in survival outcomes and safety in pts with resectable stage III NSCLC treated in 5 prospective clinical trials.
Methods
Data from 499 pts included in five Swiss Group for Clinical Cancer Research (SAKK) trials for resectable stage III NSCLC (SAKK 16/96, 16/00, 16/01, 16/08, and 16/14) were pooled. All pts were treated with 3 cycles of chemotherapy (cisplatin/docetaxel). 207 (41%) pts received neoadjuvant chemotherapy, 229 (46%) neoadjuvant radiochemotherapy and 62 (12%) neoadjuvant chemotherapy and perioperative durvalumab.
Results
158 pts (31.7%) were females, median age was 60 years, 93% were ever-smokers, 64% had non-squamous NSCLC and 99% had ECOG 0-1. Females were more likely to be never-smokers and have non-squamous NSCLC (both p= <.0.001), otherwise baseline characteristics including age and stage were balanced. Median event-free survival (EFS) (24.4 vs. 11.8 months, p=0.014) and median overall survival (OS) (59.3 vs. 26.1 months, p=0.002) were significantly longer in female compared to male pts (5y-OS 49.2% vs. 36.6%). Both remained significant in a multivariable analysis correcting for age, smoking status, treatment modality and histology (EFS: HR 1.35, OS: 1.38). However, while the cause-specific hazard of non-cancer related death was increased in males (HR=2.14, 95% CI: 1.32-3.46, p=0.0019) the risk of tumor-related death was similar between sexes (HR=1.26, 95% CI: 0.96-1.65, p=0.09). No significant differences in the proportion of treatment related grade ≥ 3 adverse events (62.5% vs. 69.7%) or treatment discontinuation (3.2% vs 3.2%) were observed between females and males. However, the proportion of dose reductions was higher in females (32% vs 23%, p=0.037). Surgical outcomes (R0-resection rate and 30-day mortality) were similar between sexes.
Conclusions
EFS and OS were improved in female pts with an excess non-tumor related mortality seen in males. No significant differences in toxicity were observed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Frehner.
Funding
Has not received any funding.
Disclosure
M. Guckenberger: Financial Interests, Institutional, Research Funding: Varian Siemens, AstraZeneca, ViewRay; Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca. M.T. Mark: Financial Interests, Institutional, Advisory Board: Janssen, Roche, Takeda, BMS, MSD, AstraZeneca, Merck; Financial Interests, Institutional, Research Grant: Gilead Science; Financial Interests, Institutional, Other, travel grant: Janssen, AstraZeneca, Roche, Takeda, Amgen. A. Addeo: Financial Interests, Personal and Institutional, Advisory Board: BMS, AstraZeneca, Boehringer Ingelheim, Roche, MSD, Pfizer, Eli Lilly, Astellas, Amgen, Novartis; Financial Interests, Personal and Institutional, Speaker’s Bureau: Eli Lilly, AstraZeneca, Amgen. S.I. Rothschild: Financial Interests, Institutional, Advisory Role: Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Merck KG, MSD, Novartis, Otsuka, Pfizer, PharmaMar, Roche, Sanofi, Takeda; Financial Interests, Institutional, Financially compensated role: Roche, BMS, AstraZeneca, Amgen, MSD, Novartis, Roche; Financial Interests, Institutional, Other, travel support: Roche, Eli Lilly, BMS, Amgen, AstraZeneca, MSD. M. Pless: Financial Interests, Personal and Institutional, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Janssen, Merck, MSD, Nestle, Novartis, Pfizer, Roche, Sanofi, Takeda, Vifor. D. König: Financial Interests, Institutional, Advisory Role: AstraZeneca, MSD, Novartis; Financial Interests, Institutional, Invited Speaker: Amgen, Mirati, Sanofi, Roche, Oncology in Motion; Financial Interests, Institutional, Advisory Board: BMS, Merck, MSD, PharmaMar, AstraZeneca; Financial Interests, Institutional, Research Grant: Geistlich-Stucki Stifung. B.C. Özdemir: Financial Interests, Institutional, Advisory Board: BMS, MSD, Merck, Ipsen, Roche, Pfizer, Novartis, Janssen, Sanofi. S. Schmid: Financial Interests, Institutional, Research Grant: Janssen, MSD, von Tobel Stiftung, Swisslife, Marlies-Schwegler Stiftung; Financial Interests, Institutional, Advisory Board: BMS, MSD, Roche, Merck, Pfizer, Sanofi, Janssen, AstraZeneca, Takeda; Financial Interests, Personal, Other, Travel grant: Roche, Takeda, Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1111P - Genomic and transcriptomic analysis of Japanese melanoma reveals candidate biomarkers for immune checkpoint inhibitor responders
Presenter: Toshihiro Kimura
Session: Poster session 04
1112P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster session 04
1113P - A machine learning model based on computed tomography radiomics to predict prognosis in subjects with stage IV melanoma
Presenter: Maria Teresa Maccallini
Session: Poster session 04
1114P - Deciphering unresectable in-transit metastasis in melanoma: Multi-modal and longitudinal insights
Presenter: Giuseppe Tarantino
Session: Poster session 04
1115P - Multiomics clustering of patients with cutaneous melanoma to reveal survival trends based on tumor immune evasion features
Presenter: Adeliya Leleytner
Session: Poster session 04
1116P - Application of the Scottish inflammatory prognostic score to the south-east Scotland cancer network real-world melanoma cohort
Presenter: Karim El-Shakankery
Session: Poster session 04
1117P - Intratumoral microbiota is associated with prognosis in Chinese patients with skin melanoma
Presenter: Hang Jiang
Session: Poster session 04
1118P - Immunological alterations during neoadjuvant BRAF/MEK inhibition in patients with prior unresectable regionally advanced melanoma: Translational analysis from the REDUCTOR trial
Presenter: Femke Burgers
Session: Poster session 04
1119P - Genomic and transcriptomic predictors of resistance to anti-PD1 monotherapy in patients with advanced melanoma
Presenter: Wenya Wang
Session: Poster session 04
1120P - Tumoral and peripheral immunophenotype of patients with stage II/III melanoma undergoing adjuvant immunotherapy following tumor resection
Presenter: Maria Ascierto
Session: Poster session 04